ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NGNE vs ACRS // FREE CASH FLOW YIELD

Neurogene Inc. (NASDAQ) VS. Aclaris Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: NGNE 2 — ACRS 3
▲ FREE CASH FLOW YIELD LEADER: ACRS
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NGNE VS. ACRS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NGNE ACRS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 73.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -13.59% -8.04% -5.55 ACRS /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -58.20% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 12.76 0.20 +12.56 NGNE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 ACRS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.3 46.1 +8.20 NGNE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $576.7M $587.3M -$10.6M ACRS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NGNE REV ACRS REV NGNE GROSS % ACRS GROSS % NGNE FCF ACRS FCF
FY 2025 $0 $7.8M — 73.3% -$78.4M -$47.2M
FY 2024 $925.0K $18.7M — 85.1% -$71.4M -$20.2M
FY 2023 $0 $31.2M — — -$51.4M -$78.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NGNE // BETA —
ACRS // BETA —